A ranked top 10 of the most common FDA Form 483 observations for drug manufacturers, built from 836 drug inspections with posted citations that ended between January 2025 and June 2026. Each entry gives the 21 CFR section, what it means in plain English, how often FDA cited it, how often inspections citing it were classified OAI, a recent Form 483 that shows it, and one prevention point. Includes the top 5 device observations under the QMSR, how a Form 483 differs from a warning letter, and where to find recent 483s.